期刊文献+

缓激肽引起的内皮源性超极化因子在调节冠状动脉阻力血管张力中的作用 被引量:3

Bradykinin-elicited hyperpolarizing factor contributes to vasodilation of coronary microcirculation
原文传递
导出
摘要 本研究用离体兔心灌注模型比较内皮源性超极化因子(EDHF)与内皮源性舒张因子(E-DRF即一氧化氮)和前列环素(PGI2)的特性。(1)注人缓激肽(Bk3~3000pmol/L)产生剂量依赖性扩张反应,以冠状动脉灌注压(CPP)下降及舒张持续时间表示。(2)联合应用NO合酶及PGI2合成酶抑制剂N-亚硝基-L-精氨酸(LNNA,0.3umol/L)和diclofenac(10umol/L),Bk引起的冠状动脉舒张反应时相明显缩短(P<0.05~0.001),而CPP降低无明显改变(P>0.05)。(3)上述基础上加用钾通道阻滞剂-阿帕明(1umol/L),结果Bk引起的CPP下降及冠状动脉舒张反应时间均被显著抑制(P<0.05或P<0.01),且该抑制用灌流方法清除阿帕明后解除。(4)应用LNNA-diclofenac基础上,阿帕明对EDRF类似物—S-亚硝基-L-半胱氨酸(1nmol/L)引起的CPP下降及扩张反应时相均无明显影响(P>0.05)。(5)依次应用LNNA、diclofenac和阿帕明,基础CPP分别提高29%、8%和60%。本研究结果提示:①Bk引起兔冠状动脉阻力血管扩张;②Bk触发的非E? The purpose of the study was to compare the dilatory characteristics of endotheliumderived hyperpolarizing factor (EDHF) with endothe liumderived relaxing factor (EDRF) and prostacyclin (PGI2) in isolated, constantflow perfused rabbit heart. Bradykinin (BK, 33000 pmol/L) was orderly injected in bolus, and repeated under concomitant application of diclofenac and LNNA, then was also applied in administration of diclofenac, LNNA and apamin (1umol/L), an antagonist of K+channel. Furthermore, CYSNO (1nmol/L), an EDRFmimetic, was applied to LNNAdiclofenac resistant relaxation to observe if apamin affects its effect. It showed that apamin had no influence on CYSNO. Finally, LNNA, diclofenac and apamin were orderly used. Results showed a series of dosedependent dilatory responses to Bk in terms of decrease in coronary perfusion pressure (CPP) and time course of relaxation. The time course of the response to Bk was markedly shortened (P<0.05~001) whereas the peak decrease in CPP had no significant change under coadministration of LNNAdiclofenac. In contrast, the decrease in CPP as well as the time course of LNNAdiclofenac insensitive dilatation was significantly blocked by apamin(P<0.05 or P<0.01). Furthermore, apamin played no significant role on dilatation to CYSNO. LNNA,diclofenac and apamin raised basal CPP by 29%, 8% and 60% respectively over control. It is concluded that: (1) There is a LNNAdiclofenac resistant relaxation to Bk in the isolated perfused rabbit heart;(2) EDHF independently contributes to the LNNAdiclofenac insensitive dilatation to Bk probably via hyperpolarization mediated by K+channel; (3) EDHF is specially responsible for the initial phase of the dilatation to Bk whereas contribution to the sustained phase features actions of EDRF and PGI2 ;(4) They jointly maintain the basal tone of the coronary resistance vesels.
作者 郑旭 潘孝仁
出处 《中华心血管病杂志》 CSCD 北大核心 1997年第6期453-456,共4页 Chinese Journal of Cardiology
关键词 内皮源性 超极化因子 EDHF 前列环素 缓激肽 Endotheliumderived hyperpolarizing factor endotheliumderived relaxing factor prostacyclin bradykinin
  • 相关文献

参考文献1

  • 1Chen G,Am J Physiol,1991年,260卷,H1888页

同被引文献39

  • 1[1]Hearse DJ, Braimbridge MV, Jynge P. Protection of the ischemic myocardium: Cardioplegia[M]. New York: Raven, 1981.
  • 2[2]Saldanha C, Hearse DJ. Coronary vascular responsiveness to 5-hydroxytryptamine before and after infusion of hyperkalemic crystalloid cardioplegic solution in the rat heart. Possible evidence of endothelial damage[J]. J Thorac Cardiovasc Surg, 1989, 8: 783-787.
  • 3[3]Guo-wei He. Hyperkalemia exposure impairs EDHF- mediated endothelial function in the human coronary artery[J]. Ann Thorac Surg, 1997, 63: 84-87.
  • 4[4]Holzmann S, Kukovetz WR, Windischhofer W, et al. Pharmacologic differentiation between endothelium-dependent relaxations sensitive and resistant to nitro-L-arginine in coronary arteries[J]. J Cardiovasc Pharmacol, 1994, 23: 747-756.
  • 5[5]Yasunobu H, Yutaka N, et al. Endothelium-derived hyperpolarizing factor activates Ca2+-activated channels in porcine coronary artery smooth muscle cells[J]. J Cardiovasc Pharmacol, 1998, 32: 642-649.
  • 6[7]He GW, Yang CQ. Hyperkalemia alters EDHF-mediated hyperpolarization and relaxation in coronary arteries[J]. Am J Physiol, 1996, 271 (Heart Circ Physiol 40): H760-767.
  • 7[8]Vanhoutte PM. Endothelium-derived hyperpolarizing factor[M]. Edited Netherlands, Harwood academic publishers, 1996,ISBN 3-7186-5929-8.
  • 8[9]Hecker M, Bara AT, Bauerschs J, et al. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals[J]. J Physiol(Lond) 1994, 481: 407-414.
  • 9[10]Campbell WB, Gebremedhin D, Pratt PF, et al. Identification of epoxyeicosatrienoic acid as endothelium-derived hyperpolarizing factors[J]. Circ Res, 1996, 78: 415-423.
  • 10[11]Holzmann S, Kukovetz WR, Windischhofer W, et al. Pharmacologic differentiation between endothelium-dependent relaxations sensitive and resistant to nitro-L-arginine in coronary arteries[J]. J Cardiovasc Pharmacol, 1994,23: 747-756.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部